

Laura Richert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6071992/publications.pdf>

Version: 2024-02-01

59
papers

1,694
citations

304368

22
h-index

301761

39
g-index

60
all docs

60
docs citations

60
times ranked

3540
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. <i>PLoS Medicine</i> , 2022, 19, e1003865.	3.9	27
2	Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). <i>Clinical Microbiology and Infection</i> , 2022, 28, 1010-1016.	2.8	21
3	NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans. <i>Vaccines</i> , 2022, 10, 884.	2.1	1
4	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. <i>Journal of Immunology</i> , 2022, 208, 2663-2674.	0.4	8
5	Engagement of TRAIL triggers degranulation and IFN γ production in human natural killer cells. <i>EMBO Reports</i> , 2022, 23, .	2.0	12
6	Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 493-506.	4.6	115
7	Influence of the Antiretroviral Regimen on the Early Changes in Plasma HIV RNA and Immune Activation at Initiation of Antiretroviral Therapy in Naïve HIV-1 Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, e146-e149.	0.9	0
8	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. <i>PLoS Medicine</i> , 2021, 18, e1003813.	3.9	34
9	Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect. <i>Journal of Immunological Methods</i> , 2020, 477, 112711.	0.6	2
10	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	1.3	7
11	Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1290-1301.	4.6	34
12	Distinct Signatures in the Receptor Repertoire Discriminate CD56 ^{bright} and CD56 ^{dim} Natural Killer Cells. <i>Frontiers in Immunology</i> , 2020, 11, 568927.	2.2	12
13	In-depth characterization of monocyte subsets during the course of healthy pregnancy. <i>Journal of Reproductive Immunology</i> , 2020, 141, 103151.	0.8	9
14	The Transcription Factor Promyelocytic Leukemia Zinc Finger Protein Is Associated With Expression of Liver-Homing Receptors on Human Blood CD56 ^{bright} Natural Killer Cells. <i>Hepatology Communications</i> , 2020, 4, 409-424.	2.0	7
15	PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 585-597.	4.6	84
16	Evaluation of the template letter regarding the disclosure of genetic information within the family in France. <i>Journal of Community Genetics</i> , 2019, 10, 489-499.	0.5	7
17	A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor Nkp44. <i>Nature Immunology</i> , 2019, 20, 1129-1137.	7.0	59
18	Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression. <i>Journal of Virology</i> , 2019, 93, .	1.5	21

#	ARTICLE	IF	CITATIONS
19	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. <i>Lancet HIV</i> , 2019, 6, e334-e340.	2.1	5
20	Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals. <i>Frontiers in Immunology</i> , 2019, 10, 874.	2.2	11
21	Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. <i>PLoS ONE</i> , 2019, 14, e0209911.	1.1	19
22	The SCDâ€Well randomized controlled trial: Effects of a mindfulnessâ€based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 737-745.	1.8	26
23	Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 519-526.	0.9	5
24	HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates. <i>PLoS ONE</i> , 2018, 13, e0207794.	1.1	11
25	Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture. <i>Gastroenterology</i> , 2018, 155, 1366-1371.e3.	0.6	36
26	Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 481-490.	0.9	1
27	Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. <i>International Journal of Infectious Diseases</i> , 2018, 74, 83-96.	1.5	21
28	Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71. <i>PLoS ONE</i> , 2018, 13, e0201170.	1.1	46
29	Innate immune responses to toll-like receptor stimulation are altered during the course of pregnancy. <i>Journal of Reproductive Immunology</i> , 2018, 128, 30-37.	0.8	28
30	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. <i>Cell Reports</i> , 2017, 20, 2251-2261.	2.9	107
31	Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavirâ€Ritonavir Plus Either Raltegravir or Tenofovirâ€Emtricitabine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 185-192.	0.9	7
32	Language features in the acute phase of poststroke severe aphasia could predict the outcome. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2017, 53, 249-255.	1.1	20
33	Proliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells. <i>PLoS ONE</i> , 2017, 12, e0182532.	1.1	27
34	Optimization and evaluation of Luminex performance with supernatants of antigen-stimulated peripheral blood mononuclear cells. <i>BMC Immunology</i> , 2016, 17, 44.	0.9	10
35	Changes in HIV-1 Capsid Stability Induced by Common Cytotoxic-T-Lymphocyte-Driven Viral Sequence Mutations. <i>Journal of Virology</i> , 2016, 90, 7579-7586.	1.5	8
36	Host and disease factors are associated with cognitive function in European <sc>HIV</sc>-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PLoS ONE, 2016, 11, e0152952.	1.1	4
38	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PLoS ONE, 2016, 11, e0153484.	1.1	20
39	No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults. PLoS ONE, 2016, 11, e0168640.	1.1	8
40	Recent developments in clinical trial designs for HIV vaccine research. Human Vaccines and Immunotherapeutics, 2015, 11, 1022-1029.	1.4	7
41	Decreased HIV-Specific T-Regulatory Responses Are Associated with Effective DC-Vaccine Induced Immunity. PLoS Pathogens, 2015, 11, e1004752.	2.1	23
42	Diabetes and cognitive decline in a French cohort of patients infected with HIV-1. Neurology, 2015, 85, 1065-1073.	1.5	23
43	Bone mineral density and inflammatory and bone biomarkers after darunavir+ritonavir combined with either raltegravir or tenofovir+emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV, 2015, 2, e464-e473.	2.1	69
44	Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T cell immunity associated with control of viral load. European Journal of Immunology, 2014, 44, 2802-2810.	1.6	102
45	Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. Aids, 2014, 28, 1593-1602.	1.0	28
46	Decline in locomotor functions over time in HIV-infected patients. Aids, 2014, 28, 1441-1449.	1.0	42
47	Ritonavir-boosted darunavir combined with raltegravir or tenofovir+emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet, The, 2014, 384, 1942-1951.	6.3	158
48	Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials, 2014, 15, 68.	0.7	11
49	Handgrip Strength Is Only Weakly Correlated With Physical Function in Well-Controlled HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e25-e27.	0.9	3
50	Is the current use of "positivity"™ thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?. Aids, 2013, 27, 1362-1365.	1.0	2
51	Selective Determinants of Low Bone Mineral Mass in Adult Women with Anorexia Nervosa. International Journal of Endocrinology, 2013, 2013, 1-9.	0.6	16
52	Cognitive disorders in HIV-infected patients. Aids, 2013, 27, 391-400.	1.0	125
53	Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. Aids, 2013, 27, 1421-1431.	1.0	16
54	High frequency of poor locomotor performance in HIV-infected patients. Aids, 2011, 25, 797-805.	1.0	65

#	ARTICLE	IF	CITATIONS
55	Early post-transplantation hypophosphatemia is associated with elevated FGF-23 levels. <i>European Journal of Endocrinology</i> , 2011, 164, 839-847.	1.9	35
56	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. <i>Clinical Trials</i> , 2010, 7, 19-35.	0.7	33
57	A randomized double-blind placebo-controlled trial to investigate the effects of nasal calcitonin on bone microarchitecture measured by high-resolution peripheral quantitative computerized tomography in postmenopausal women " Study protocol. <i>Trials</i> , 2008, 9, 19.	0.7	3
58	Methodological issues of non-inferiority trials in HIV-infected patients: a need for consensus?. <i>Aids</i> , 2008, 22, 996-997.	1.0	2
59	Bone Mass in Prepubertal Boys Is Associated with a Gln223Arg Amino Acid Substitution in the Leptin Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4380-4386.	1.8	42